


Patent Docket P0894P1D2C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Joffre Baker et al.  Serial No.: 09/896,856  Filed: 29 June 2001  For: CARDIAC HYPERTROPHY FACTOR AND USES THEREFOR	Group Art Unit: not yet assigned  Examiner: not yet assigned
CERTIFICATE UNDER 37 CFR 1.10 <u>EL 142012563 US Express Mail</u>  I hereby certify that this correspondence and related documents is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patent and Trademarks, Washington, D.C. 20231 January 18, 2002  Yvonne Carter	

Letter and REQUEST TO USE COMPUTER-READABLE SEQUENCE LISTING  
UNDER 37 CFR §1.821(e)

Assistant Commissioner of Patents  
Washington, D.C. 20231


Sir:

Applicants respectfully request that the compliant computer-readable Sequence Listing filed in application Serial No. 08/733,850 be used as the computer-readable Sequence Listing for the present, above-identified application.

The paper copy of the Sequence Listing filed in the present application is identical to the computer-readable copy of the Sequence Listing filed in the application Serial No. 08/733,850 .

Respectfully submitted,

GENENTECH, INC.

By:   
Deirdre L. Conley, Ph.D.  
Reg. No. 36,487  
Telephone No. (650) 225-2066

Date: January 18, 2002



09157

- given for only non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

By:   
Deirdre L. Conley, Ph.D.  
Reg. No. 36,487  
Telephone No. (650) 225-2066

Date: January 18, 2002



09157

PATENT TRADEMARK OFFICE  
Doc. 103523